TNBC is resistant to common breast cancer therapies, as it lacks the expression of the most common breast cancer targets, namely estrogen receptor (ER), human epidermal growth factor receptor-2 (HER2), and progesterone receptor (PR) [2,3]. This evidence concerns the gene ERBB2 and breast cancer.